Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment
N Duma, R Santana-Davila, JR Molina - Mayo Clinic Proceedings, 2019 - Elsevier
Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer …
decade, significant advances have been made in the science of non–small cell lung cancer …
[HTML][HTML] Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of
patients with several tumor types, but predicting patient benefit using approved diagnostics …
patients with several tumor types, but predicting patient benefit using approved diagnostics …
Biomarkers of response to PD-1 pathway blockade
The binding of T cell immune checkpoint proteins programmed death 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) to their ligands allows immune evasion by …
T-lymphocyte-associated protein 4 (CTLA-4) to their ligands allows immune evasion by …
Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes
Computational methods have made substantial progress in improving the accuracy and
throughput of pathology workflows for diagnostic, prognostic, and genomic prediction. Still …
throughput of pathology workflows for diagnostic, prognostic, and genomic prediction. Still …
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment
B Wu, X Shi, M Jiang, H Liu - Molecular Cancer, 2023 - Springer
Ongoing research has revealed that the existence of cancer stem cells (CSCs) is one of the
biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor …
biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor …
Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose …
J Xu, Y Zhang, RU Jia, C Yue, L Chang, R Liu… - Clinical Cancer …, 2019 - AACR
Purpose: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and
apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced …
apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced …
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
M Nishino, NH Ramaiya, H Hatabu… - Nature reviews Clinical …, 2017 - nature.com
Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm
shift in the treatment of advanced-stage cancers. The promising antitumour activity of …
shift in the treatment of advanced-stage cancers. The promising antitumour activity of …